EC1167 - CAS 1610414-00-0

EC1167 - CAS 1610414-00-0 Catalog number: BADC-01496

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

EC1167 is the linker for EC1169 which is a PSMA-targeted tubulysin B-containing conjugate.

Category
ADCs Linker
Product Name
EC1167
CAS
1610414-00-0
Catalog Number
BADC-01496
Molecular Formula
C33H45N7O17S
Molecular Weight
843.81
EC1167

Ordering Information

Catalog Number Size Price Quantity
BADC-01496 -- $-- Inquiry
Description
EC1167 is the linker for EC1169 which is a PSMA-targeted tubulysin B-containing conjugate.
Synonyms
(2S)-2-[[(1S)-1-carboxy-5-[[4-[2-[[(2S)-3-carboxy-1-[[(2S)-3-carboxy-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]phenyl]methylcarbamoylamino]pentyl]carbamoylamino]pentanedioic acid
IUPAC Name
(2S)-2-[[(1S)-1-carboxy-5-[[4-[2-[[(2S)-3-carboxy-1-[[(2S)-3-carboxy-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]phenyl]methylcarbamoylamino]pentyl]carbamoylamino]pentanedioic acid
Canonical SMILES
C1=CC(=CC=C1CC(=O)NC(CC(=O)O)C(=O)NC(CC(=O)O)C(=O)NC(CS)C(=O)O)CNC(=O)NCCCCC(C(=O)O)NC(=O)NC(CCC(=O)O)C(=O)O
InChI
InChI=1S/C33H45N7O17S/c41-23(36-20(12-25(44)45)27(48)37-21(13-26(46)47)28(49)38-22(15-58)31(54)55)11-16-4-6-17(7-5-16)14-35-32(56)34-10-2-1-3-18(29(50)51)39-33(57)40-19(30(52)53)8-9-24(42)43/h4-7,18-22,58H,1-3,8-15H2,(H,36,41)(H,37,48)(H,38,49)(H,42,43)(H,44,45)(H,46,47)(H,50,51)(H,52,53)(H,54,55)(H2,34,35,56)(H2,39,40,57)/t18-,19-,20-,21-,22-/m0/s1
InChIKey
NAFZHTBVPLIASG-YFNVTMOMSA-N
Storage
solvent: -80°C 12 months; Powder: -20°C 3 years

EC1167 is a cutting-edge chemical linker designed to connect small molecule drugs with larger bioactive compounds, enhancing their therapeutic potential. In drug discovery, this linker serves as a critical component in the synthesis of drug conjugates, which are at the forefront of precision medicine. Drug conjugates utilize the specificity of targeting agents to deliver potent cytotoxic compounds directly to diseased cells, minimizing collateral damage to healthy tissue. As a versatile linker, EC1167 plays a pivotal role in stabilizing these conjugates while allowing for the controlled release of the drug payload upon reaching its target.

The design of EC1167 leverages advanced chemistry to address the challenges encountered in the development of drug conjugates, including stability, solubility, and bioavailability. It is engineered to endure systemic circulation, ensuring that the drug conjugates remain intact until they encounter their specific target. Once at the target site, EC1167 facilitates the selective release of the tubulysin B payload, a microtubule inhibitor, which is particularly effective against proliferating cancer cells. This precise mode of action underscores EC1167’s importance in enhancing the efficacy and safety profile of drug conjugates in oncology therapeutic strategies.

Moreover, EC1167 is integral to the efficacy of EC1169, a PSMA-targeted tubulysin B-containing conjugate. EC1169 utilizes EC1167 to specifically target and bind to the Prostate-Specific Membrane Antigen (PSMA) expressed on prostate cancer cells. By doing so, EC1167 not only enhances target specificity but also ensures that the cytotoxic effects of tubulysin B are confined to cancer cells, thus maximizing anti-tumor activity while minimizing off-target toxicity. This targeted approach is critical in developing treatments that offer greater clinical benefits with a reduced risk of side effects compared to conventional chemotherapy.

In the broader context of drug discovery, EC1167 exemplifies the innovation and precision that modern medicinal chemistry strives to achieve. The ability to create highly specific and effective drug conjugates opens new horizons for treating a range of diseases that were previously difficult to manage. As the field continues to evolve, linkers like EC1167 will remain central to developing next-generation therapeutics that harness the potential of targeted drug delivery systems. In summary, EC1167 not only advances the therapeutic capabilities of conjugated drugs but also represents a significant leap towards more personalized and effective healthcare solutions.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Why Choose BOC Sciences?

Customer Support

Providing excellent 24/7 customer service and support

Project Management

Offering 100% high-quality services at all stages

Quality Assurance

Ensuring the quality and reliability of products or services

Global Delivery

Ensuring timely delivery of products worldwide

Questions & Comments
Verification code
Send Inquiry
Verification code
Resources & Supports
Inquiry Basket